Mutual of America Capital Management LLC Has $397,000 Stock Holdings in QuidelOrtho Co. (NASDAQ:QDEL)

Mutual of America Capital Management LLC lowered its holdings in QuidelOrtho Co. (NASDAQ:QDEL) by 69.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,696 shares of the company’s stock after selling 19,680 shares during the quarter. Mutual of America Capital Management LLC’s holdings in QuidelOrtho were worth $397,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Leeward Investments LLC MA increased its holdings in shares of QuidelOrtho by 17.1% during the third quarter. Leeward Investments LLC MA now owns 229,847 shares of the company’s stock worth $10,481,000 after buying an additional 33,588 shares in the last quarter. Hsbc Holdings PLC lifted its position in QuidelOrtho by 316.2% during the 2nd quarter. Hsbc Holdings PLC now owns 28,916 shares of the company’s stock worth $962,000 after buying an additional 21,968 shares in the last quarter. WINTON GROUP Ltd bought a new stake in QuidelOrtho during the 2nd quarter worth about $4,669,000. Vanguard Group Inc. grew its stake in shares of QuidelOrtho by 0.8% during the first quarter. Vanguard Group Inc. now owns 4,879,143 shares of the company’s stock valued at $233,906,000 after purchasing an additional 37,733 shares during the last quarter. Finally, Maverick Capital Ltd. increased its stake in shares of QuidelOrtho by 27.5% in the 2nd quarter. Maverick Capital Ltd. now owns 1,728,913 shares of the company’s stock valued at $57,434,000 after buying an additional 372,662 shares during the period. 99.00% of the stock is currently owned by institutional investors.

Insider Buying and Selling at QuidelOrtho

In other news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $35.31, for a total transaction of $291,667,061.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.00% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on QDEL shares. Craig Hallum upgraded QuidelOrtho from a “hold” rating to a “buy” rating and raised their price target for the company from $40.00 to $57.00 in a report on Thursday, September 5th. UBS Group assumed coverage on shares of QuidelOrtho in a research note on Thursday, September 19th. They issued a “neutral” rating and a $50.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price target on shares of QuidelOrtho in a research report on Friday, August 16th. Finally, William Blair reissued a “market perform” rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to MarketBeat, QuidelOrtho currently has a consensus rating of “Hold” and a consensus target price of $58.83.

QuidelOrtho Trading Up 0.3 %

NASDAQ:QDEL opened at $41.12 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81. QuidelOrtho Co. has a fifty-two week low of $29.74 and a fifty-two week high of $75.86. The business’s 50-day simple moving average is $41.07 and its 200-day simple moving average is $40.27. The stock has a market capitalization of $2.77 billion, a PE ratio of -1.47 and a beta of 0.12.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Thursday, November 7th. The company reported $0.85 EPS for the quarter, beating the consensus estimate of $0.30 by $0.55. QuidelOrtho had a negative net margin of 66.25% and a positive return on equity of 4.24%. The business had revenue of $727.00 million for the quarter, compared to analysts’ expectations of $642.16 million. During the same period in the previous year, the firm posted $0.90 EPS. The firm’s revenue was down 2.3% compared to the same quarter last year. Sell-side analysts expect that QuidelOrtho Co. will post 1.73 earnings per share for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.